文献速递造血干细胞移植与细胞治疗淋巴瘤

瞬时抗体靶向CD45RC抑制移植物抗宿主病的发生

Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease.
PubMed 文献 · Blood Adv · 2020-01-01

异基因骨髓移植后急性GVHD发生率30%至50%,由产生炎性细胞因子的效应T细胞介导。本研究在大鼠、小鼠及人T细胞介导的异种GVHD模型中证明,体外去除CD45RChigh T细胞或体内短程抗CD45RC单克隆抗体治疗均可抑制急性GVHD,且不消除抗肿瘤效应和抗病毒免疫记忆。

要点

  • 体外去除CD45RChigh T细胞或短程抗CD45RC单抗体内治疗均抑制急性和异种GVHD。
  • 抗人CD45RC单抗不消除人记忆抗病毒免疫应答,体外试验不触发细胞因子释放。
  • 抗人CD45RC单抗联合雷帕霉素可能成为治疗急性GVHD而不消除抗肿瘤效应的新疗法。

核心结论

  • 抗人CD45RC单克隆抗体联合雷帕霉素的预防性治疗有潜力成为治疗急性GVHD而不消除抗肿瘤效应的新疗法。

研究设计与样本

  • 在大鼠和小鼠异基因GVHD模型以及NSG小鼠中人T细胞介导的异种GVHD模型中开展的研究。

主要发现

  • 在大鼠和小鼠异基因GVHD及人T细胞介导的NSG小鼠异种GVHD中,体外去除CD45RChigh T细胞和体内短程抗CD45RC单抗治疗均抑制急性GVHD。
  • 大鼠模型中,接受抗CD45RC单抗治疗的长期存活动物供体细胞完全植入并产生供体特异性耐受。
  • 输注人细胞并接受抗CD45RC单抗治疗的NSG小鼠中验证了人肿瘤的排斥。
  • 抗人CD45RC单抗未消除人记忆抗病毒免疫应答,体外试验中未触发细胞因子释放。

临床怎么用

  • 作者认为,抗人CD45RC单抗联合雷帕霉素的预防性治疗可作为治疗急性GVHD而不消除抗肿瘤效应的新疗法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic bone marrow transplantation (BMT) is a widely spread treatment of many hematological diseases, but its most important side effect is graft-versus-host disease (GVHD). Despite the development of new therapies, acute GVHD (aGVHD) occurs in 30% to 50% of allogeneic BMT and is characterized by the generation of effector T (Teff) cells with production of inflammatory cytokines. We previously demonstrated that a short anti-CD45RC monoclonal antibody (mAb) treatment in a heart allograft rat model transiently decreased CD45RChigh Teff cells and increased regulatory T cell (Treg) number and function allowing long-term donor-specific tolerance. Here, we demonstrated in rat and mouse allogeneic GVHD, as well as in xenogeneic GVHD mediated by human T cells in NSG mice, that both ex vivo depletion of CD45RChigh T cells and in vivo treatment with short-course anti-CD45RC mAbs inhibited aGVHD. In the rat model, we demonstrated that long surviving animals treated with anti-CD45RC mAbs were fully engrafted with donor cells and developed a donor-specific tolerance. Finally, we validated the rejection of a human tumor in NSG mice infused with human cells and treated with anti-CD45RC mAbs. The anti-human CD45RC mAbs showed a favorable safety profile because it did not abolish human memory antiviral immune responses, nor trigger cytokine release in in vitro assays. Altogether, our results show the potential of a prophylactic treatment with anti-human CD45RC mAbs in combination with rapamycin as a new therapy to treat aGVHD without abolishing the antitumor effect.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Boucault L, Lopez Robles MD, Thiolat A, et al. Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease. Blood Adv. 2020. PMID: 32511714. doi:10.1182/bloodadvances.2020001688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。